Extending the Spectrum of Precompetitive Collaboration in Oncology Research Workshop Summary

Afbeeldingen

Artikel vergelijken

  • Engels
  • Paperback
  • 9780309156547
  • 15 oktober 2010
  • 112 pagina's
Alle productspecificaties

Samenvatting

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings. Table of Contents Front Matter Workshop Summary Acronyms Glossary Appendix A: Workshop Agenda Appendix B: Polling Results

Productspecificaties

Inhoud

Taal
en
Bindwijze
Paperback
Oorspronkelijke releasedatum
15 oktober 2010
Aantal pagina's
112
Illustraties
Nee

Betrokkenen

Hoofdauteur
Institute Of Medicine
Hoofdredacteur
Erin Balogh
Tweede Redacteur
Sharyl J. Nass
Co Redacteur
Margie Patlak
Hoofduitgeverij
National Academies Press

Overige kenmerken

Editie
1
Studieboek
Nee
Verpakking breedte
152 mm
Verpakking hoogte
229 mm
Verpakking lengte
229 mm
Verpakkingsgewicht
181 g

EAN

EAN
9780309156547

Je vindt dit artikel in

Taal
Engels
Studieboek of algemeen
Studieboeken
Boek, ebook of luisterboek?
Boek
Nog geen reviews

Kies gewenste uitvoering

Bindwijze : Paperback

Prijsinformatie en bestellen

Niet leverbaar

Ontvang eenmalig een mail of notificatie via de bol app zodra dit artikel weer leverbaar is.

Houd er rekening mee dat het artikel niet altijd weer terug op voorraad komt.

Lijst met gekozen artikelen om te vergelijken

Vergelijk artikelen